Loading clinical trials...
Loading clinical trials...
Phase I Trial of CART123 Cells Given in Combination With Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Conditions
Interventions
CART123 Cells
Ruxolitinib 10 MG
+1 more
Locations
1
United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Start Date
February 28, 2025
Primary Completion Date
March 1, 2045
Completion Date
March 1, 2045
Last Updated
January 16, 2026
NCT06307054
NCT06022003
NCT05428969
NCT06359002
NCT07471841
NCT06763666
Lead Sponsor
University of Pennsylvania
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions